Pooled data from 7 randomized trials showed liraglutide significantly reduced the albumin-to-creatinine ratio by 11.76 mg/g in type 2 diabetes patients, with greatest benefit in younger patients with poor blood sugar control.
-11.76 mg/g ACR reductionPooled across 7 randomized trials, liraglutide significantly reduced this kidney damage marker compared to controls in type 2 diabetes patients
What the researchers found
Across seven RCTs involving 473 participants, liraglutide significantly reduced the albumin-to-creatinine ratio compared to controls (weighted mean difference: -11.76 mg/g, 95% CI -21.71 to -1.81, P = 0.02). Heterogeneity was substantial (I² = 75%).
Subgroup analyses identified populations with the greatest benefit: patients with HbA1c > 8.0%, treatment duration > 12 weeks, and age < 60 years all showed significant ACR reductions. Meta-regression found that no single variable (sample size, HbA1c, baseline ACR, duration, or dose) explained the heterogeneity. Sensitivity analysis confirmed stable results, and no publication bias was detected (Begg's P = 0.46, Egger's P = 0.57).
Why it matters
Diabetic kidney disease is the leading cause of kidney failure worldwide, and early kidney damage is detected by elevated ACR — often before patients have any symptoms. This meta-analysis provides pooled evidence from the highest-quality study type (RCTs) that liraglutide protects kidneys in type 2 diabetes beyond what might be expected from blood sugar control alone. This supports using liraglutide as a dual-benefit therapy for diabetes patients at risk of kidney complications.
How the study worked
This systematic review and meta-analysis searched PubMed, Embase, Cochrane Library, WanFang, and CNKI databases through November 2024 for randomized controlled trials comparing liraglutide to controls (placebo or active drugs) in type 2 diabetes patients, with ACR as an outcome. Seven RCTs with 473 participants met inclusion criteria. Data were pooled using random-effects models due to heterogeneity. Subgroup analyses, meta-regression, sensitivity analyses, and publication bias assessments (Begg's and Egger's tests) were performed. The review was registered on PROSPERO.
What this study cannot tell us
The meta-analysis included only 7 trials with 473 participants — a relatively small evidence base. The substantial heterogeneity (I² = 75%) suggests meaningful differences between studies that random-effects models may not fully address. The included trials varied in design, comparators, and patient populations. Meta-regression could not identify the source of heterogeneity. The ACR is a surrogate endpoint — longer-term studies examining hard kidney outcomes (dialysis, transplant) would be more definitive.
How to read the evidence
This is a meta-analysis of randomized controlled trials — the highest level of evidence in the evidence hierarchy. However, the small number of included trials (7), moderate total sample size (473), and substantial heterogeneity somewhat limit the strength of the conclusions. The results are consistent with large cardiovascular outcome trials showing GLP-1 kidney benefits.
When this study was published
Published in 2025 with a literature search through November 2024, this is a very current synthesis of the available evidence on liraglutide's kidney effects.
The bigger picture
This meta-analysis adds to the growing body of evidence supporting GLP-1 receptor agonists as kidney-protective agents in diabetes. While large outcome trials like LEADER showed liraglutide reduces major kidney events, this analysis focuses specifically on ACR — an earlier, more sensitive marker of kidney damage. The finding that younger patients with poorer glycemic control benefit most could help clinicians target liraglutide therapy to patients who would gain the greatest kidney protection.
Questions still open
- Does liraglutide's ACR reduction translate to reduced progression to end-stage kidney disease in longer-term studies?
- Why do younger patients benefit more — is this related to earlier disease stage or differences in GLP-1 receptor expression?
- How does liraglutide's kidney-protective effect compare to semaglutide and other GLP-1 agonists on the ACR endpoint?
Common questions
What is the albumin-to-creatinine ratio and why does it matter?
Should all diabetic patients take liraglutide to protect their kidneys?
Read the original research
Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.
European journal of medical research, 30(1), 652
Citation
Wang, Feng; Xu, Guangzhong; Feng, Wei; Qu, Gengbao; Li, Pengyu; Li, Kai. (2025). Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.. European journal of medical research, 30(1), 652. https://doi.org/10.1186/s40001-025-02801-2